PLAZMA ATEROJENİK İNDEKSİN DİYABETES MELLİTUS TİPLERİ ARASINDA KARŞILAŞTIRILMASI
Özet Görüntüleme: 197
/ 
PDF İndirme: 230
DOI:
https://doi.org/10.26809/joa.2018548678Anahtar Kelimeler:
Plasma atherogenic index, diabetes mellitus, atherosclerosisÖzet
Objective: Diabetes mellitus (DM) is a chronic metabolic disease that affects several systems and organs. Diabetic dyslipemia is considered to be one of the major macrovascular complications of DM. Plasma atherogenic index (PAI) is considered as an independent determining factor for cardiovascular disease (CVD). The aim of this study was to compare the PAI values between Type-1 DM and type-2 DM patient groups.
Material and Method: The study data were obtained by scanning the files of 58 patients who applied to the cardiology outpatient clinic within the last one year retrospectively. The patients were divided into two groups as 20 patients in Type-1 DM group and 38 patients in Type-2 DM group. PAI was obtained by taking logarithm of plasma triglyceride divided by plasma high density lipoprotein.
Results: PAI was 0.29±0.31 in type-1 DM group and PAI 0.62±0.35 in type-2 DM group (p=0.001).
Conclusion: PAI, which is an important predictor of CVD, was found to be higher in patients with type-2 DM than those with type-1 DM.
Keywords: Plasma atherogenic index, diabetes mellitus, atherosclerosis
İndirmeler
Referanslar
Bulut T., 2017, The prevalence of dyslipidemia and associated factors in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metab, 30(2), 181–187.
Dobiasova M., 2006, Atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice, Vnitr Lek, 52, 64-71.
Dobiasova M., 2011, Cholesterol esterification and atherogenic index of plasma correlate with
lipoprotein size and findings on coronary angiography, J Lipid Res, 52, 566-571.
Ettinger WH., 1992, Lipoprotein lipids in older people: results from the Cardiovascular Health Study, Circulation, 86, 858-869.
Guariguata L., 2014, Global estimates of diabetes prevalence for 2013 and projections for 2035, Diabetes Res Clin Pract, 103:137–149.
Isomaa B., 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683–689.
Kahn SE., 2013, Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present and future. Lancet, 383, 1068-1083.
Schaefer EJ., 1994, Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study, J Lipid Res, 35(5), 779-792.
Taskinen MR., 2003, Diabetic dyslipidaemia: from basic research to clinical practice, Diabetologia 46, 733–774.
Turner RC., 1988, Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23), BMJ 316, 823–828.
Verges B., 2015, Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia, 58, 886–899.
Zimmet PZ., 2014, Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2, 56–64.
İndir
Yayınlanmış
Nasıl Atıf Yapılır
Sayı
Bölüm
Lisans
Yazarlar, makale Journal of Awareness’de yayınlanmak üzere kabul edildiğinde.makalenin içeriğindeki tüm telif haklarını, Rating Academy Ar-Ge Yazılım Yayıncılık Eğitim Danışmanlık ve Organizasyon Ticaret Ltd. Şti’ne devrederler. Yazarlar, patent hakları gibi telif hakkı dışındaki tüm mülkiyet haklarını saklı tutar.
Bu makalede yazar olarak listelenen herkes çalışmaya önemli, doğrudan, entelektüel katkılar yapmış olmalı ve bunun için kamu sorumluluğu almalıdır.
Bu makale daha once yayınlanmamış ve başka dergilerde yayınlanmak üzere gönderilmemiştir.
